MISSISSAUGA, ON, March 9,
2023 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF) an advanced medical
technologies company, today announced the results of the matters
voted upon at its Fiscal 2022 Annual and Special Meeting of
Shareholders ("AGM") held March 8,
2023.
Shareholders voted in favour of all items of business and each
item of business was approved by the requisite number of votes. The
matters included the election of the Board of Directors, the
appointment of auditors, and the approval of the Company's Omnibus
Long-Term Incentive Plan. The total number of shares represented,
either in person or by proxy, totaled 12,803,487 or 51.076%.
The voting results are detailed below.
1) The Election of the Board of Directors
Name of
Nominee
|
Votes FOR
|
%
|
Votes
WITHHELD
|
%
|
Amir Boloor
|
11,592,631
|
92.275
|
970,546
|
7.725
|
Joseph
Cordiano
|
12,322,807
|
98.087
|
240,370
|
1.913
|
Martin
Goldfarb
|
12,268,607
|
97.655
|
294,570
|
2.345
|
Samantha
Nutt
|
11,686,821
|
93.024
|
876,356
|
6.976
|
Brian Pedlar
|
11,575,121
|
92.135
|
988,056
|
7.865
|
Abe Schwartz
|
12,268,607
|
97.655
|
294,570
|
2.345
|
Ron Smith
|
11,536,231
|
91.826
|
1,026,946
|
8.174
|
2) The Appointment of the Auditor
|
Votes FOR
|
%
|
Votes
WITHHELD
|
%
|
PricewaterhouseCoopers,
LLP
|
12,696,487
|
99.996
|
500
|
0.004
|
3) The Approval of the Company's 2023 Omnibus Long-Term
Incentive Plan
|
Votes FOR
|
%
|
Votes
WITHHELD
|
%
|
Omnibus Long-Term
Incentive Plan
|
11,445,341
|
91.102
|
1,117,836
|
8.898
|
Final voting results of all matters voted on at the meeting will
be filed on SEDAR at www.sedar.com and further details of the voted
matters can be found in the Company's management information
circular dated February 1, 2023.
For those interested in learning more about Covalon's solutions,
visit www.covalon.com or follow Covalon on LinkedIn, Facebook,
Instagram or Twitter.
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device
company, built on the relentless pursuit to help the most
vulnerable patients have a better chance at healing. Through a
strong portfolio of patented technologies and solutions for
advanced wound care, infection prevention, and medical device
coatings, we offer innovative, gentler, and more compassionate
options for patients to heal with less infections, less pain, and
better outcomes. Our solutions are designed for patients and made
for care providers. Covalon leverages its patented medical
technology platforms and expertise in two ways: (i) by developing
products that are sold under Covalon's name; and (ii) by developing
and commercializing medical products for other medical companies
under development and license contracts. The Company is listed on
the TSX Venture Exchange, having the symbol COV and trades on the
OTCQX Market under the symbol CVALF. To learn more about Covalon,
visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements which
reflect the Company's current expectations regarding future events.
The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results "may",
"could", "would", "might", "will" or "will be taken", "occur", or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which
is available on the Company's profile at www.sedar.com, any of
which could cause results, performance, or achievements to differ
materially from the results discussed or implied in the
forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The forward-looking
statements contained in this news release are made as of the date
of this news release, and the Company assumes no obligation to
update or alter any forward-looking statements, whether as a result
of new information, further events, or otherwise, except as
required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-announces-voting-results-from-fiscal-2022-annual-and-special-meeting-of-shareholders-301767840.html
SOURCE Covalon Technologies Ltd.